×
About 18,820 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  7,661 results

The contribution of pre-existing spinal pseudarthrosis to the surgical correction for t...
https://doi.org/10.1016/j.jocn.2020.11.006
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia; Qiao M, Qian BP et. al.

Dec 2nd, 2020 - The correction of global kyphosis (GK) for ankylosing spondylitis (AS) patients with pre-existing pseudarthrosis were frequently over 45°. Mismatch between kyphosis correction of GK and pedicle subtraction osteotomy (PSO) may be ascribed to contri...

Positive association of Parkinson's disease with ankylosing spondylitis: a nationwide p...
https://doi.org/10.1186/s12967-020-02629-w
Journal of Translational Medicine; Yeh FC, Chen HC et. al.

Dec 1st, 2020 - Ankylosing spondylitis (AS) is characterized by excessive production of inflammatory cytokines. Recent evidence suggests that inflammation underlies the neurodegenerative process of Parkinson's disease (PD). Whether AS has an influence on the deve...

One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in S...
https://doi.org/10.1002/acr.24523
Arthritis Care & Research; Glintborg B, Lindstrom U et. al.

Nov 30th, 2020 - To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi), in patients with spondyloarthritis (SpA) using adalimumab as the main comparator. Observational, prospective...

Cancer diagnosis and mortality in patients with ankylosing spondylitis: A Western Austr...
https://doi.org/10.1111/1756-185X.14036
International Journal of Rheumatic Diseases REFERENCES; Kelty E, Raymond W et. al.

Nov 30th, 2020 - Ankylosing spondylitis (AS) has been associated with a modest increase in the risk of cancer. However, little is known as to how AS influences risk of mortality following cancer diagnosis. This study compared the risk of cancer and subsequent mort...

Association of Core Muscle Endurance Times With Balance, Fatigue, Physical Activity Lev...
https://doi.org/10.1097/RHU.0000000000001641
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases; Sarac DC, Bayram S et. al.

Nov 30th, 2020 - Core muscle endurance (CME), which is the ability of sustaining the activity of trunk muscles, has been shown to be lower in patients with ankylosing spondylitis (AS). The aim was to investigate the possible relationship between CME times and bala...

see more →

Guidelines  37 results

2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis ...
https://www.rheumatology.org/Portals/0/Files/AxialSpA-Guideline-2019.pdf
Ward MM,et al

Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
http://www.samsungbioepis.com/en/newsroom/detail/FDA-Approves-ETICOVO-Samsung-Bioepis-Second-Anti-TNF-Medicine.html

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guidelin...
https://www.rheumatology.org/Portals/0/Files/ACR-AAHKS-Perioperative-Management-Guideline.pdf
Goodman, S.,et al

Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.

see more →

Drugs  1,073 results see all →

Clinicaltrials.gov  9,229 results

The contribution of pre-existing spinal pseudarthrosis to the surgical correction for t...
https://doi.org/10.1016/j.jocn.2020.11.006
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia; Qiao M, Qian BP et. al.

Dec 2nd, 2020 - The correction of global kyphosis (GK) for ankylosing spondylitis (AS) patients with pre-existing pseudarthrosis were frequently over 45°. Mismatch between kyphosis correction of GK and pedicle subtraction osteotomy (PSO) may be ascribed to contri...

Positive association of Parkinson's disease with ankylosing spondylitis: a nationwide p...
https://doi.org/10.1186/s12967-020-02629-w
Journal of Translational Medicine; Yeh FC, Chen HC et. al.

Dec 1st, 2020 - Ankylosing spondylitis (AS) is characterized by excessive production of inflammatory cytokines. Recent evidence suggests that inflammation underlies the neurodegenerative process of Parkinson's disease (PD). Whether AS has an influence on the deve...

One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in S...
https://doi.org/10.1002/acr.24523
Arthritis Care & Research; Glintborg B, Lindstrom U et. al.

Nov 30th, 2020 - To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi), in patients with spondyloarthritis (SpA) using adalimumab as the main comparator. Observational, prospective...

Cancer diagnosis and mortality in patients with ankylosing spondylitis: A Western Austr...
https://doi.org/10.1111/1756-185X.14036
International Journal of Rheumatic Diseases REFERENCES; Kelty E, Raymond W et. al.

Nov 30th, 2020 - Ankylosing spondylitis (AS) has been associated with a modest increase in the risk of cancer. However, little is known as to how AS influences risk of mortality following cancer diagnosis. This study compared the risk of cancer and subsequent mort...

Association of Core Muscle Endurance Times With Balance, Fatigue, Physical Activity Lev...
https://doi.org/10.1097/RHU.0000000000001641
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases; Sarac DC, Bayram S et. al.

Nov 30th, 2020 - Core muscle endurance (CME), which is the ability of sustaining the activity of trunk muscles, has been shown to be lower in patients with ankylosing spondylitis (AS). The aim was to investigate the possible relationship between CME times and bala...

see more →

News  769 results

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
https://www.staging.medscape.com/viewarticle/940709

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
https://www.medscape.com/viewarticle/940709

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588_4

Jul 1st, 2020 - The age of onset of AS is usually from the late teens to 40 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Insidious onset of low back pain is the most common ...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588_1

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

see more →

Patient Education  51 results see all →